1Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron,2002, 92: 635-651.
2Usui H, Shikata K, Matsuda M, et al.HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant,2003, 18: 265-272.
3Zoja C, Corna D, Rottoli D, et al. Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int, 2002, 61: 1635-1645.
4Cooper ME, Vranes D, Youssel S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes, 1999, 48:2229-2239.
5Hoshi S, Shu Y, Yoshida F, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest, 2002, 82 :25-35.
6Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int, 1999,56:1627-1637.
7Kim SI, Han DC, Lee HB. Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol, 2000, 11:80-87.
8Reed MJ, Meszaros K, Entes LJ, et al. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type Ⅱ diabetes. Diabetelogia, 1999,42:102-106.
9Katoh M, Kurosawa Y, Tanaka K, et al. Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol, 2001, 281: H655-660.
10Aoyama I, Shimokata K, Niwa T. An oral absorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron, 2002, 92: 635-651.
